Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29476017)

  • 21. Hypoxia imaging with
    Melsens E; De Vlieghere E; Descamps B; Vanhove C; Kersemans K; De Vos F; Goethals I; Brans B; De Wever O; Ceelen W; Pattyn P
    Radiat Oncol; 2018 Mar; 13(1):39. PubMed ID: 29514673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
    Hong CR; Wilson WR; Hicks KO
    Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
    Hunter FW; Young RJ; Shalev Z; Vellanki RN; Wang J; Gu Y; Joshi N; Sreebhavan S; Weinreb I; Goldstein DP; Moffat J; Ketela T; Brown KR; Koritzinsky M; Solomon B; Rischin D; Wilson WR; Wouters BG
    Cancer Res; 2015 Oct; 75(19):4211-23. PubMed ID: 26297733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells.
    Maekawa H; Miyoshi H; Yamaura T; Itatani Y; Kawada K; Sakai Y; Taketo MM
    Mol Cancer Ther; 2018 Oct; 17(10):2187-2196. PubMed ID: 29970483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
    Saggar JK; Tannock IF
    Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.
    Peeters SG; Zegers CM; Biemans R; Lieuwes NG; van Stiphout RG; Yaromina A; Sun JD; Hart CP; Windhorst AD; van Elmpt W; Dubois LJ; Lambin P
    Clin Cancer Res; 2015 Jul; 21(13):2984-92. PubMed ID: 25805800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer.
    Kim HG; Kim CW; Lee DH; Lee JS; Oh ET; Park HJ
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302.
    Takakusagi Y; Matsumoto S; Saito K; Matsuo M; Kishimoto S; Wojtkowiak JW; DeGraff W; Kesarwala AH; Choudhuri R; Devasahayam N; Subramanian S; Munasinghe JP; Gillies RJ; Mitchell JB; Hart CP; Krishna MC
    PLoS One; 2014; 9(9):e107995. PubMed ID: 25254649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [
    McNeal KC; Reeves KM; Song PN; Lapi SE; Sorace AG; Larimer BM
    Nucl Med Biol; 2024; 134-135():108918. PubMed ID: 38772123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
    Nesbitt H; Byrne NM; Williams SN; Ming L; Worthington J; Errington RJ; Patterson LH; Smith PJ; McKeown SR; McKenna DJ
    Clin Cancer Res; 2017 Apr; 23(7):1797-1808. PubMed ID: 27697998
    [No Abstract]   [Full Text] [Related]  

  • 31. Evofosfamide, a new horizon in the treatment of pancreatic cancer.
    Pourmorteza M; Rahman ZU; Young M
    Anticancer Drugs; 2016 Sep; 27(8):723-5. PubMed ID: 27232101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the "steal" phenomenon on the efficacy of hypoxia activated prodrug TH-302 in pancreatic cancer.
    Bailey KM; Cornnell HH; Ibrahim-Hashim A; Wojtkowiak JW; Hart CP; Zhang X; Leos R; Martinez GV; Baker AF; Gillies RJ
    PLoS One; 2014; 9(12):e113586. PubMed ID: 25532146
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Reeves KM; Song PN; Angermeier A; Della Manna D; Li Y; Wang J; Yang ES; Sorace AG; Larimer BM
    Clin Cancer Res; 2022 Jan; 28(2):327-337. PubMed ID: 34615724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
    Hegde A; Jayaprakash P; Couillault CA; Piha-Paul S; Karp D; Rodon J; Pant S; Fu S; Dumbrava EE; Yap TA; Subbiah V; Bhosale P; Coarfa C; Higgins JP; Williams ET; Wilson TF; Lim J; Meric-Bernstam F; Sumner E; Zain H; Nguyen D; Nguyen LM; Rajapakshe K; Curran MA; Hong DS
    Clin Cancer Res; 2021 Jun; 27(11):3050-3060. PubMed ID: 33771853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional CRISPR and shRNA Screens Identify Involvement of Mitochondrial Electron Transport in the Activation of Evofosfamide.
    Hunter FW; Devaux JBL; Meng F; Hong CR; Khan A; Tsai P; Ketela TW; Sharma I; Kakadia PM; Marastoni S; Shalev Z; Hickey AJR; Print CG; Bohlander SK; Hart CP; Wouters BG; Wilson WR
    Mol Pharmacol; 2019 Jun; 95(6):638-651. PubMed ID: 30979813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
    Portwood S; Lal D; Hsu YC; Vargas R; Johnson MK; Wetzler M; Hart CP; Wang ES
    Clin Cancer Res; 2013 Dec; 19(23):6506-19. PubMed ID: 24088735
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure.
    Francipane MG; Bulanin D; Lagasse E
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
    Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.
    Malkomes P; Lunger I; Luetticke A; Oppermann E; Haetscher N; Serve H; Holzer K; Bechstein WO; Rieger MA
    Ann Surg Oncol; 2016 Sep; 23(9):2849-57. PubMed ID: 27059026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting response to combination evofosfamide and immunotherapy under hypoxic conditions in murine models of colon cancer.
    Lima EABF; Song PN; Reeves K; Larimer B; Sorace AG; Yankeelov TE
    Math Biosci Eng; 2023 Sep; 20(10):17625-17645. PubMed ID: 38052529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.